[
    [
        {
            "time": "",
            "original_text": "泰格医药明日招股：高瓴资本淡马锡加持 要不要打新",
            "features": {
                "keywords": [
                    "泰格医药",
                    "高瓴资本",
                    "淡马锡",
                    "招股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "泰格医药明日招股：高瓴资本淡马锡加持 要不要打新",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-08-06",
            "original_text": "中证指数公司：8月6日发布中证兴业证券ESG盈利100指数",
            "features": {
                "keywords": [
                    "中证指数",
                    "ESG",
                    "盈利100指数"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "证券"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中证指数公司：8月6日发布中证兴业证券ESG盈利100指数",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药股千亿市值企业达19家，这个领域“黑马”频出",
            "features": {
                "keywords": [
                    "医药股",
                    "千亿市值",
                    "黑马"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药股千亿市值企业达19家，这个领域“黑马”频出",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "大消费盘前早知道：剑南春东方红提价",
            "features": {
                "keywords": [
                    "大消费",
                    "剑南春",
                    "东方红",
                    "提价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "大消费盘前早知道：剑南春东方红提价",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "关于核准无锡药明康德新药开发股份有限公司发行境外上市外资股的批复",
            "features": {
                "keywords": [
                    "药明康德",
                    "境外上市",
                    "批复"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "关于核准无锡药明康德新药开发股份有限公司发行境外上市外资股的批复",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-07-19",
            "original_text": "在A股打拼了近8年、高瓴资本热捧的泰格医药于7月19日通过了港交所聆讯，据说本周将开始招股。大家都说泰格医药是国内CRO(药物研发外包服务)龙头企业，但我们似乎已经知道国内的CRO龙头企业是药明康德、康龙化成，但为什么还称泰格为国内CRO龙头企业呢？另外，泰格医药有什么过人之处让高瓴资本两次购买其股份呢？",
            "features": {
                "keywords": [
                    "泰格医药",
                    "高瓴资本",
                    "CRO",
                    "龙头企业",
                    "港交所"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "在A股打拼了近8年、高瓴资本热捧的泰格医药于7月19日通过了港交所聆讯，据说本周将开始招股。大家都说泰格医药是国内CRO(药物研发外包服务)龙头企业，但我们似乎已经知道国内的CRO龙头企业是药明康德、康龙化成，但为什么还称泰格为国内CRO龙头企业呢？另外，泰格医药有什么过人之处让高瓴资本两次购买其股份呢？",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本再次加仓的泰格医药是一家什么样的企业?",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "泰格医药",
                    "加仓"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "高瓴资本再次加仓的泰格医药是一家什么样的企业?",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "专访微芯生物董事长鲁先平：创新药“拓荒”19年虽千万人吾往矣",
            "features": {
                "keywords": [
                    "微芯生物",
                    "创新药",
                    "鲁先平",
                    "拓荒"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "专访微芯生物董事长鲁先平：创新药“拓荒”19年虽千万人吾往矣",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]